KOD Kodiak Sciences
- 3.740
- 0.0000.00%
- 3.850
- +0.110+2.94%
Kodiak Sciences News
Kodiak Sciences (KOD) Receives a Sell From Barclays
Kodiak Sciences (KOD.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.82 dollars, previous value of -1.35 dollars, expected value of -1.07 dollars.
Kodiak Sciences (KOD.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -0.82 dollars, previous value of -1.35 dollars, expected value of -1.07 dollars.
Kodiak Sciences | 10-Q: Quarterly report
Kodiak Sciences 1Q Loss/Shr 82c >KOD
Kodiak Sciences 1Q Loss/Shr 82c >KOD
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif., May 15, 2024 PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Scie
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make
Kodiak Sciences Dosing Subjects in Phase III Trial of Diabetic Retinopathy Drug
Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, annou
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
PALO ALTO, Calif., May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline Including Advancements With High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. KSI-501 clinical and non-clinical data hig
BGC, DRS and AMTX Are Among After Hour Movers
Kodiak Sciences Is Maintained at Neutral by UBS
Kodiak Sciences Is Maintained at Neutral by UBS
UBS Maintains Neutral on Kodiak Sciences, Raises Price Target to $5
UBS analyst Eliana Merle maintains Kodiak Sciences with a Neutral and raises the price target from $3 to $5.
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript
Kodiak Sciences Is Maintained at Underweight by Barclays
Kodiak Sciences Is Maintained at Underweight by Barclays
Barclays Maintains Underweight on Kodiak Sciences, Raises Price Target to $3
Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.
Kodiak Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 -44.24% Barclays $2 → $3 Maintains Underweight 12/21/2023 -44.24% UBS $4 → $3 Maintains Neutral
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Walgreens Boots Alliance (WBA) and Kodiak Sciences (KOD)
Barclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)
Analysis
Price Target
No Data
